Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Mus musculus | RAR-related orphan receptor gamma | Starlite/ChEMBL | No references |
Homo sapiens | survival of motor neuron 2, centromeric | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | Get druggable targets OG5_132873 | All targets in OG5_132873 |
Echinococcus multilocularis | survival motor neuron protein 1 | Get druggable targets OG5_132873 | All targets in OG5_132873 |
Brugia malayi | hypothetical protein | Get druggable targets OG5_132873 | All targets in OG5_132873 |
Echinococcus granulosus | survival motor neuron protein 1 | Get druggable targets OG5_132873 | All targets in OG5_132873 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Leishmania major | glycosyl hydrolase-like protein | 0.0145 | 0.0685 | 0.5 |
Brugia malayi | hypothetical protein | 0.0286 | 0.1789 | 0.3051 |
Loa Loa (eye worm) | alpha-L-fucosidase | 0.0803 | 0.5865 | 1 |
Trypanosoma cruzi | endo-beta-N-acetylglucosaminidase, putative | 0.0145 | 0.0685 | 0.5 |
Brugia malayi | hypothetical protein | 0.0071 | 0.0102 | 0.0173 |
Trichomonas vaginalis | alpha-L-fucosidase, putative | 0.0352 | 0.2316 | 0.5 |
Trichomonas vaginalis | alpha-L-fucosidase, putative | 0.0352 | 0.2316 | 0.5 |
Onchocerca volvulus | 0.0058 | 0 | 0.5 | |
Echinococcus granulosus | survival motor neuron protein 1 | 0.0286 | 0.1789 | 0.1705 |
Brugia malayi | Alpha-L-fucosidase family protein | 0.0803 | 0.5865 | 1 |
Echinococcus multilocularis | fucosidase, alpha L 1, tissue | 0.1329 | 1 | 1 |
Echinococcus granulosus | endo beta n-acetylglucosaminidase | 0.0145 | 0.0685 | 0.0589 |
Echinococcus multilocularis | survival motor neuron protein 1 | 0.0286 | 0.1789 | 0.1705 |
Loa Loa (eye worm) | hypothetical protein | 0.0286 | 0.1789 | 0.2132 |
Trypanosoma brucei | endo-beta-N-acetylglucosaminidase, putative | 0.0145 | 0.0685 | 0.5 |
Trypanosoma cruzi | endo-beta-N-acetylglucosaminidase, putative | 0.0145 | 0.0685 | 0.5 |
Brugia malayi | Glycosyl hydrolase family 85 protein | 0.0145 | 0.0685 | 0.1167 |
Mycobacterium ulcerans | alpha-L-fucosidase | 0.1329 | 1 | 0.5 |
Echinococcus multilocularis | endo beta n-acetylglucosaminidase | 0.0145 | 0.0685 | 0.0589 |
Schistosoma mansoni | alpha-l-fucosidase | 0.0803 | 0.5865 | 1 |
Schistosoma mansoni | endo beta n-acetylglucosaminidase | 0.0145 | 0.0685 | 0.1167 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (functional) | = 21.7 uM | PUBCHEM_BIOASSAY: Dose Response confirmation of activators of hexokinase domain containing I (HKDC1) in the hexokinase 1 selectivity assay. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493187, AID493207] | ChEMBL. | No reference |
EC50 (functional) | = 34.1 uM | PUBCHEM_BIOASSAY: Dose Response confirmation of activators of hexokinase domain containing I (HKDC1). (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493187, AID493207] | ChEMBL. | No reference |
Potency (functional) | = 0.5623 um | PUBCHEM_BIOASSAY: VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 1.4125 um | PUBCHEM_BIOASSAY: qHTS Assay for Enhancers of SMN2 Splice Variant Expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 9.285 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.